IVERIC bio, Inc. (NASDAQ:ISEE) is expected to report third quarter earnings results, before market open, on Monday 2nd November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.22 per share.
Looking ahead, the full year loss are expected at $ 0.92 per share.
Stock Performance
On Friday, shares of IVERIC bio, Inc. has traded high as $ 6.24 and has cracked $ 5.87 on the downward trend, reaching $ 5.92 with volume of 537.80 thousand shares.
According to the previous trading day, closing price of $ 5.92, representing a 131.06 % increase from the 52 week low of $ 2.64 and a 32 % decrease over the 52 week high of $ 8.97.
The company has a market capital of $ 529.86 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
IVERIC bio, Inc. will be hosting a conference call at 8:00 AM eastern time on 2nd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website ivericbio.com
IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD). It is also developing High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitors for the treatment of GA secondary to dry AMD and other age-related retinal diseases, such as wet AMD and idiopathic polypoidal choroidal vasculopathy.
